GRAY Graybug Vision, Inc.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve.

$2.56
As of 11/30/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  09/25/2020
Outstanding shares:  21,319,635
Average volume:  198,723
Market cap:   $57,563,015
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    38942Q103
ISIN:        US38942Q1031
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.75
PS ratio:   0.00
Return on equity:   -50.32%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy